Journal of Lipid and Atherosclerosis最新文献_第4页

Discrepant Effect of High-Density Lipoprotein Cholesterol on the Hematologic Malignancy Risk: A Nationwide Cohort Study. 高密度脂蛋白胆固醇对血液恶性肿瘤风险的不同影响：一项全国性队列研究。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.12997/jla.2025.14.1.94

Su Youn Nam, Junwoo Jo, Won Kee Lee

{"title":"Discrepant Effect of High-Density Lipoprotein Cholesterol on the Hematologic Malignancy Risk: A Nationwide Cohort Study.","authors":"Su Youn Nam, Junwoo Jo, Won Kee Lee","doi":"10.12997/jla.2025.14.1.94","DOIUrl":"10.12997/jla.2025.14.1.94","url":null,"abstract":"Objective: Although high-density lipoprotein cholesterol (HDL-C) is inversely associated with hematologic malignancies, modification by smoking has not been reported. We investigated how smoking and menopausal status modify these association.Methods: This population-based cohort study enrolled cancer-free individuals who underwent a national cancer screening in 2010 and followed up until December 2017. HDL-C levels were classified into eight groups based on 10 mg/dL intervals: (<30, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, or ≥90 mg/dL).Results: Among 4,517,892 participants, 5887 had lymphoma, 3348 had leukemia, and 12151 had unspecified hematologic malignancies. The adjusted hazard ratios (aHRs) for the lowest HDL-C levels compared to the 70-79 mg/dL range were 1.83 (1.45-2.31) for lymphoma, 3.14 (2.41-4.08) for leukemia, and 2.34 (2.01-2.72) for unspecified hematologic malignancy. The effects of low HDL-C levels on hematologic malignancies were similar in both men and women. Low HDL-C levels were associated with a higher risk of leukemia regardless of smoking status, but extremely high HDL-C levels were linked to a higher risk of leukemia (aHR, 2.32; 95% confidence interval [95% CI], 1.18-4.55) only in current smokers.The hazardous effect of low HDL-C levels on lymphoma was significant only in never smokers (aHR, 2.01; 95% CI, 1.51-2.68). Hazardous effects of low HDL-C levels on leukemia were observed only in post-menopausal women (aHR, 2.94; 95% CI, 1.69-5.11).Conclusion: Low HDL-C levels were associated with a higher risk of leukemia and lymphoma, with discrepancies based on smoking and menopausal status.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"94-105"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect. 糖尿病性心肌病的分子途径及降糖药物的作用

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.12997/jla.2025.14.1.54

Jie-Eun Lee, Byung Gyu Kim, Jong Chul Won

引用次数: 0

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. 管理代谢功能障碍相关脂肪变性肝病患者血脂异常的实用方法

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-06-26 DOI: 10.12997/jla.2025.14.1.5

Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira

{"title":"Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira","doi":"10.12997/jla.2025.14.1.5","DOIUrl":"10.12997/jla.2025.14.1.5","url":null,"abstract":"Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"5-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter Regarding Article, Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction? 他汀类替格瑞洛和横纹肌溶解：是巧合还是药物相互作用？

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.12997/jla.2025.14.1.130

Jai Bharat Sharma, Ramesh Patel

引用次数: 0

Journal of Lipid and Atherosclerosis Update 2025. 脂质和动脉粥样硬化杂志更新2025。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.12997/jla.2025.14.1.3

Ji Hye Heo, In-Kyung Jeong

引用次数: 0

Letter by Isa Ardahanli Regarding Article, Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction? Isa Ardahanli关于他汀类药物替格瑞洛和横纹肌溶解：是巧合还是药物相互作用？

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.12997/jla.2025.14.1.128

Isa Ardahanli, Murat Ozmen

引用次数: 0

Corrigendum to Previously Published Articles. 先前发表文章的勘误表。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-14 DOI: 10.12997/jla.2025.14.1.132

引用次数: 0

Therapeutic Vaccines and Nucleic Acid Drugs for Cardiovascular Disease. 治疗心血管疾病的疫苗和核酸药物。

Journal of Lipid and Atherosclerosis Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.12997/jla.2024.13.3.328

Hironori Nakagami, Hiroki Hayashi, Ryuichi Morishita

{"title":"Therapeutic Vaccines and Nucleic Acid Drugs for Cardiovascular Disease.","authors":"Hironori Nakagami, Hiroki Hayashi, Ryuichi Morishita","doi":"10.12997/jla.2024.13.3.328","DOIUrl":"10.12997/jla.2024.13.3.328","url":null,"abstract":"To combat the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel vaccine modalities, such as messenger RNA vaccines, were rapidly developed and have shown high efficacy. This new vaccine technology, underpinned by intensive immunological analysis, is now being applied to the production of other vaccines. For over 10 years, we have been developing therapeutic vaccines for non-infectious diseases. The epitope vaccine approach, which combines a B-cell epitope with exogenous T-cell epitopes presented through major histocompatibility complex molecules, has been proposed to induce antibody production. This vaccine type is designed to efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. If therapeutic vaccines become established as treatment options for conditions such as hypertension or dyslipidemia, their administration-potentially only a few times per year-could replace the need for daily medication. Nucleic acid drugs, including small interfering RNA and antisense oligonucleotides, have recently received attention as long-term agonists, similar to vaccines. Therefore, therapeutic vaccines or nucleic acid drugs could represent a novel strategy for controlling the progression of cardiovascular diseases. It is hoped that the accumulation of immunological findings and advances in vaccine technology will provide valuable insights into the development of vaccines for treating cardiovascular diseases.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"13 3","pages":"328-337"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024 KSoLA Consensus on Secondary Dyslipidemia. 2024 KSoLA 继发性血脂异常共识。

Journal of Lipid and Atherosclerosis Pub Date : 2024-09-01 Epub Date: 2024-09-04 DOI: 10.12997/jla.2024.13.3.215

Hoyoun Won, Jae Hyun Bae, Hyunjung Lim, Minji Kang, Minjoo Kim, Sang-Hak Lee

引用次数: 0

Extracellular Vesicles as Mediators in Atherosclerotic Cardiovascular Disease. 细胞外小泡是动脉粥样硬化性心血管疾病的介质。

Journal of Lipid and Atherosclerosis Pub Date : 2024-09-01 Epub Date: 2024-08-26 DOI: 10.12997/jla.2024.13.3.232

Lucia Zisser, Christoph J Binder

引用次数: 0